Diese Seite wurde automatisch übersetzt und die Genauigkeit der Übersetzung wird nicht garantiert. Bitte wende dich an die englische Version für einen Quelltext.

Conduction System Pacing Versus Conventional Right Ventricular Pacing in Adults With Atrioventricular Block

17. November 2026 aktualisiert von: Sheba Medical Center

Randomized Prospective Comparison of Conduction System Pacing Versus Conventional Right Ventricular Pacing in Patients With an Indication for Permanent Pacemaker Implantation

This study compares two ways of pacing the heart in adults with atrioventricular block, a condition in which electrical signals do not pass normally from the upper to the lower heart chambers. Participants must need a permanent pacemaker and have a left ventricular ejection fraction of at least 50% before implantation. Ejection fraction measures how much blood the main pumping chamber ejects with each beat.

The study will include 150 participants at Sheba Medical Center. By chance, 50 participants will receive conduction system pacing, which aims to stimulate the heart through its natural electrical conduction system, and 100 will receive conventional right ventricular pacing. Participants and treating clinicians will know which treatment is used.

The main question is whether the two pacing strategies differ in heart pumping function 24 months after implantation, taking the starting measurement into account. Researchers will also compare quality of life, heart-related emergency visits and hospitalizations, complications, pacemaker and lead function, repeat procedures, and use of healthcare resources.

Heart pumping function will be measured before implantation and at 12 and 24 months. Participants will complete the AQUAREL quality-of-life questionnaire before implantation and at 12, 24, 36, 48, and 60 months. Device follow-up will include routine clinical care and remote monitoring.

Studienübersicht

Detaillierte Beschreibung

Outcomes Over Devices is a prospective, randomized, open-label, two-arm, single-center study comparing conduction system pacing (CSP) with conventional right ventricular pacing (RVP). The clinical indication for permanent pacing is established before recruitment. Randomization is 1:2 (50 CSP; 100 RVP), using a concealed computer-generated sequence with variable block sizes, stratified by baseline left ventricular ejection fraction (LVEF) of 50-59% versus at least 60%, without fixed quotas per stratum.

The primary analysis follows the intention-to-treat principle. The primary estimand is the between-arm difference in LVEF at 24 months, adjusted for baseline LVEF and stratification factors as appropriate. Post-baseline measurements at 12 and 24 months will be analyzed using a repeated-measures model with treatment arm, time, and their interaction. The 12-month evaluation is exploratory. The three AQUAREL domains will be scored and analyzed separately, with baseline adjustment and multiplicity addressed for the secondary 24-month comparisons. Detailed modeling and sensitivity analyses will be prespecified in the statistical analysis plan before unblinded comparative analyses.

Failure to achieve the allocated pacing strategy will not itself exclude a participant. Alternative pacing may be used when clinically necessary, with reasons and actual treatment documented; original allocation remains the basis for intention-to-treat analysis where possible. Actual ventricular pacing burden will be recorded and evaluated in prespecified secondary analyses. An independent Clinical Events Adjudication Committee will review prespecified clinical and device-related events, with arm masking where feasible.

The study is initiated by Sheba Medical Center. Medtronic does not fund the study; CSP systems are purchased under a discounted commercial arrangement. A separate, potentially outcome-based commercial reconciliation after 12 months does not determine clinical treatment or alter randomization, follow-up, data collection, analysis, or publication independence.

Studientyp

Interventionell

Einschreibung (Geschätzt)

150

Phase

  • Unzutreffend

Kontakte und Standorte

Dieser Abschnitt enthält die Kontaktdaten derjenigen, die die Studie durchführen, und Informationen darüber, wo diese Studie durchgeführt wird.

Studienkontakt

Studienorte

      • Tel HaShomer, Israel
        • Sheba Medical Center
        • Hauptermittler:
          • Yair Edden, MD

Teilnahmekriterien

Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.

Zulassungskriterien

Studienberechtigtes Alter

18 Jahre und älter (Erwachsene, Älterer Erwachsener)

Akzeptiert gesunde Freiwillige

Nein

Studienberechtigte Geschlechter

Alle

Beschreibung

Inclusion Criteria:

  • Age 18 years or older.
  • Clinical indication for permanent pacemaker implantation due to atrioventricular block.
  • Pre-implantation echocardiographic left ventricular ejection fraction of at least 50%.
  • Ability to understand the study and sign informed consent.

Exclusion Criteria:

  • Unable to provide informed consent.
  • Estimated life expectancy of less than 12 months.
  • Severe medical condition likely to prevent completion of follow-up.
  • Existing indication for cardiac resynchronization therapy at recruitment.
  • Required pacing system or treatment incompatible with either study arm.
  • Concurrent interventional study likely to materially affect study outcomes.

Studienplan

Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.

Wie ist die Studie aufgebaut?

Designdetails

  • Hauptzweck: Behandlung
  • Zuteilung: Zufällig
  • Interventionsmodell: Parallele Zuordnung
  • Maskierung: Keine (Offenes Etikett)

Waffen und Interventionen

Teilnehmergruppe / Arm
Intervention / Behandlung
Experimental: Conduction System Pacing

50 participants allocated to conduction system pacing using a Medtronic SelectSecure MRI SureScan Model 3830 lead placed at the His bundle or left bundle branch area. Final lead position and programming are determined by the implanting electrophysiologist according to anatomy, electrical measurements, and clinical judgment.

Permanent pacing using a Medtronic SelectSecure MRI SureScan Model 3830 lead targeting His-bundle or left bundle branch area pacing. Final lead placement, fixation, and programming follow electrophysiological measurements and clinical judgment. Where feasible, the same pacemaker generator platform is used in both study arms.

Aktiver Komparator: Conventional Right Ventricular Pacing

100 participants allocated to conventional right ventricular pacing using a standard pacing lead and conventional right ventricular lead position, according to usual clinical practice at the study center. Other medical treatment and device programming are determined by clinical need.

Permanent pacemaker implantation with a conventional right ventricular pacing lead placed at a standard right ventricular site according to usual clinical practice at Sheba Medical Center. Device programming and accompanying medical treatment are determined by clinical need.

Was misst die Studie?

Primäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Left Ventricular Ejection Fraction at 24 Months
Zeitfenster: 24 months after pacemaker implantation.

Left ventricular ejection fraction (LVEF), expressed as a percentage and measured by echocardiography at 24 months after implantation. The primary comparison is the between-arm difference adjusted for baseline LVEF and stratification factors as appropriate. The primary analysis follows the intention-to-treat principle.

24 months after pacemaker implantation.

Sekundäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Change From Baseline in AQUAREL Chest Discomfort Domain Score
Zeitfenster: Before pacemaker implantation (baseline) and at 12, 24, 36, 48, and 60 months after implantation.

Change from baseline in the AQUAREL chest discomfort domain, scored separately using the original algorithm. Domain scores range from 0 to 100; higher scores indicate better quality of life and positive changes indicate improvement. The secondary between-arm comparison at 24 months is adjusted for baseline domain score, with multiplicity addressed across the three domains. The 12-month analysis is exploratory; longer-term scores are also collected.

Before pacemaker implantation (baseline) and at 12, 24, 36, 48, and 60 months after implantation.
Change From Baseline in AQUAREL Arrhythmia Domain Score
Zeitfenster: Before pacemaker implantation (baseline) and at 12, 24, 36, 48, and 60 months after implantation.

Change from baseline in the AQUAREL arrhythmia domain, scored separately using the original algorithm. Domain scores range from 0 to 100; higher scores indicate better quality of life and positive changes indicate improvement. The secondary between-arm comparison at 24 months is adjusted for baseline domain score, with multiplicity addressed across the three domains. The 12-month analysis is exploratory; longer-term scores are also collected.

Before pacemaker implantation (baseline) and at 12, 24, 36, 48, and 60 months after implantation.
Change From Baseline in AQUAREL Exertional Dyspnea Domain Score
Zeitfenster: Before pacemaker implantation (baseline) and at 12, 24, 36, 48, and 60 months after implantation.

Change from baseline in the AQUAREL exertional dyspnea domain, scored separately using the original algorithm. Domain scores range from 0 to 100; higher scores indicate better quality of life and positive changes indicate improvement. The secondary between-arm comparison at 24 months is adjusted for baseline domain score, with multiplicity addressed across the three domains. The 12-month analysis is exploratory; longer-term scores are also collected.

Before pacemaker implantation (baseline) and at 12, 24, 36, 48, and 60 months after implantation.
Ventricular Pacing Burden
Zeitfenster: Day 1 At pacemaker implantation and at 6, 12, and 24 months after implantation.

Percentage of ventricular beats paced, obtained from device interrogation. Actual pacing burden is an explanatory secondary variable and is not a randomization criterion.

Day 1 At pacemaker implantation and at 6, 12, and 24 months after implantation.
Ventricular Pacing Capture Threshold
Zeitfenster: Day 1 At pacemaker implantation and at 6, 12, and 24 months after implantation.

Ventricular capture threshold, expressed in volts, measured during device interrogation. Measurements are recorded with the corresponding device settings to assess pacing performance over follow-up.

Day 1 At pacemaker implantation and at 6, 12, and 24 months after implantation.
Ventricular Sensing Amplitude
Zeitfenster: Day 1 At pacemaker implantation and at 6, 12, and 24 months after implantation.

Amplitude of sensed ventricular signals, expressed in millivolts, measured during device interrogation to assess lead and device performance over follow-up.

Day 1 At pacemaker implantation and at 6, 12, and 24 months after implantation.
Cardiac or Pacing/Procedure-Related Emergency Department Visits
Zeitfenster: From pacemaker implantation through 24 months after implantation (cumulative event count).

Number of emergency department visits related to cardiac disease, pacing, or the implantation procedure. Relevant events will be reviewed by the Clinical Events Adjudication Committee under definitions established before enrollment.

From pacemaker implantation through 24 months after implantation (cumulative event count).
Cardiac or Pacing/Procedure-Related Hospitalizations
Zeitfenster: From pacemaker implantation through 24 months after implantation (cumulative event count).

Number of hospital admissions related to cardiac disease, pacing, or the implantation procedure. Relevant events will be reviewed by the Clinical Events Adjudication Committee under definitions established before enrollment.

From pacemaker implantation through 24 months after implantation (cumulative event count).
Heart Failure Events
Zeitfenster: From pacemaker implantation through 24 months after implantation (cumulative event count).

Number of heart failure events during follow-up, reviewed by the Clinical Events Adjudication Committee. Written event definitions and adjudication procedures will be established before enrollment as specified in the protocol.

From pacemaker implantation through 24 months after implantation (cumulative event count).
Additional Cardiac Interventions
Zeitfenster: From pacemaker implantation through 24 months after implantation (cumulative event count).

Number of additional cardiac interventions during follow-up. The indication, date, effects on LVEF or the pacing system, lead changes, and subsequent management will be recorded. Medically necessary interventions are permitted in either study arm.

From pacemaker implantation through 24 months after implantation (cumulative event count).
Device-, Lead-, and Procedure-Related Complications
Zeitfenster: From pacemaker implantation through 24 months after implantation (cumulative event count).

Number of device-, lead-, and procedure-related complications. Events include implantation complications and lead or device problems such as infection, bleeding, pneumothorax, perforation or tamponade, lead dislodgement or fracture, insulation failure, and failure to capture or sense. Major events and relatedness will be reviewed by the Clinical Events Adjudication Committee.

From pacemaker implantation through 24 months after implantation (cumulative event count).
Repeat Pacing Procedures, Lead Revisions or Replacements, and System Upgrades
Zeitfenster: From pacemaker implantation through 24 months after implantation (cumulative event count).

Number of repeat procedures involving the pacing system, including lead revision or replacement and system upgrade. Procedure type, indication, date, and resulting changes to the pacing system will be documented. Events will be reviewed by the Clinical Events Adjudication Committee.

From pacemaker implantation through 24 months after implantation (cumulative event count).
Immediate Implantation Success
Zeitfenster: During the index implantation procedure

Successful implantation of the allocated pacing strategy, reported as the number and percentage of participants meeting the arm-specific technical success criteria. For CSP, assessment includes electrophysiological evidence of conduction-system capture, sensing, capture threshold, and impedance; RVP criteria are specified separately. Numerical thresholds and mandatory tests will be prospectively approved in the electrophysiology operational appendix before first enrollment.

During the index implantation procedure
Pacing-System Function
Zeitfenster: From implantation through 24 months

Device or lead failures identified during clinical follow-up, device interrogation, or remote monitoring, including failure to capture or sense. Failures and subsequent management will be documented and relevant events reviewed by the Clinical Events Adjudication Committee.

From implantation through 24 months
Implantation Procedure Duration
Zeitfenster: During the index pacemaker implantation procedure.

Duration of the index pacemaker implantation procedure, measured in minutes, compared between pacing strategies.

During the index pacemaker implantation procedure.
Length of Hospital Stay
Zeitfenster: Periprocedural (assessed at discharge from the hospitalization for pacemaker implantation).

Duration of the hospital stay associated with the index pacemaker implantation, measured in days.

Periprocedural (assessed at discharge from the hospitalization for pacemaker implantation).
Healthcare Resource Use
Zeitfenster: Day 1 (pacemaker implantation) through 24 months after implantation.

Healthcare resources used for implantation and follow-up, including staff time, equipment, diagnostic tests, and clinical visits. Resource categories will be recorded separately rather than combined into an unvalidated score. Detailed resource definitions and analysis procedures will be finalized in the operational procedures and statistical analysis plan.

Day 1 (pacemaker implantation) through 24 months after implantation.

Andere Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Left Ventricular Ejection Fraction at 12 Months
Zeitfenster: 12 months after implantation

Left ventricular ejection fraction (LVEF), expressed as a percentage and measured by echocardiography at 12 months after implantation. The 12-month comparison is exploratory; the prespecified primary comparison is at 24 months.

12 months after implantation

Mitarbeiter und Ermittler

Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.

Ermittler

  • Hauptermittler: Yair Edden, MD, Sheba Medical Center

Studienaufzeichnungsdaten

Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.

Haupttermine studieren

Studienbeginn (Geschätzt)

1. Dezember 2026

Primärer Abschluss (Geschätzt)

1. Dezember 2029

Studienabschluss (Geschätzt)

1. Dezember 2032

Studienanmeldedaten

Zuerst eingereicht

10. November 2026

Zuerst eingereicht, das die QC-Kriterien erfüllt hat

17. November 2026

Zuerst gepostet (Tatsächlich)

18. November 2026

Studienaufzeichnungsaktualisierungen

Letztes Update gepostet (Tatsächlich)

18. November 2026

Letztes eingereichtes Update, das die QC-Kriterien erfüllt

17. November 2026

Zuletzt verifiziert

1. November 2026

Mehr Informationen

Begriffe im Zusammenhang mit dieser Studie

Andere Studien-ID-Nummern

  • CTIL-YE-3634-26-SHEBA
  • 3634-26-SMC (Andere Kennung: Sheba Medical Center)

Plan für individuelle Teilnehmerdaten (IPD)

Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?

UNENTSCHIEDEN

Arzneimittel- und Geräteinformationen, Studienunterlagen

Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt

Nein

Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt

Ja

Produkt, das in den USA hergestellt und aus den USA exportiert wird

Ja

Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .

Abonnieren